Telehealth Only Partially Offset Decreased Primary Care Visits During Pandemic
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
TUESDAY, July 23, 2024 -- Decreases in primary care visit volume were partially offset by increasing telehealth use for all patients during the COVID-19 pandemic, according to a study published in the July/August issue of the Annals of Family Medicine.
Zachary J. Morgan, from the American Board of Family Medicine in Lexington, Kentucky, and colleagues quantified the nationwide decrease in primary care visits and increase in telehealth utilization during the pandemic and explored whether certain groups of patients were disproportionately affected. Analysis included 1.65 million patients (8.83 million visits) seen at 408 practices.
The researchers found that during the pandemic, there were decreases of 7 percent in total volume and 17 percent for in-person visit volume, yielding a 10 percent telehealth conversion ratio. The greatest decreases in visit volume were seen among pediatric patients (−24 percent), Asian patients (−11 percent), and those with more comorbidities (−9 percent). Hispanic or Latino patients (17 percent) and patients living in urban areas (12 percent) had highest telehealth usage.
"These variations [in telehealth utilization] have implications not only for the long-term consequences of the COVID-19 pandemic, but also for planners seeking to ready the primary care delivery system for any future systematic disruptions and to mitigate any potential exacerbation of existing disparities," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-07-24 03:15
Read more
- Canadian Teen Hospitalized in Critical Condition With Bird Flu
- Doctors Report First U.S. Cases of Sexually Transmitted Ringworm Rash
- Better Prepared Emergency Departments Could Save Children's Lives
- Globally, Suicide Risk Increased on Certain Days of the Week, Holidays
- Policies About Late-Career Physicians Are Considered Successful
- Genetic Testing Rate Lower for Blacks With Inherited Retinal Diseases
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions